CN1506094A - Elsholizia extract granule for treating diarrhea and its prepn - Google Patents
Elsholizia extract granule for treating diarrhea and its prepn Download PDFInfo
- Publication number
- CN1506094A CN1506094A CNA021539960A CN02153996A CN1506094A CN 1506094 A CN1506094 A CN 1506094A CN A021539960 A CNA021539960 A CN A021539960A CN 02153996 A CN02153996 A CN 02153996A CN 1506094 A CN1506094 A CN 1506094A
- Authority
- CN
- China
- Prior art keywords
- add
- preparation
- thymol
- methanol
- reference substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 24
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 16
- 239000000284 extract Substances 0.000 title description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 239000000341 volatile oil Substances 0.000 claims abstract description 12
- 238000003908 quality control method Methods 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 21
- 239000005844 Thymol Substances 0.000 claims description 19
- 229960000790 thymol Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 239000013558 reference substance Substances 0.000 claims description 15
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 14
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 14
- 235000007746 carvacrol Nutrition 0.000 claims description 14
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 238000009413 insulation Methods 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000011003 system suitability test Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 5
- 206010037660 Pyrexia Diseases 0.000 abstract description 3
- 230000007661 gastrointestinal function Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 239000003814 drug Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 20
- 241000357437 Mola Species 0.000 description 17
- 241000702670 Rotavirus Species 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008838 gegenqinlian Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 230000000741 diarrhetic effect Effects 0.000 description 5
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- WFMIUXMJJBBOGJ-UHFFFAOYSA-N Thymyl acetate Chemical compound CC(C)C1=CC=C(C)C=C1OC(C)=O WFMIUXMJJBBOGJ-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- FAMPSKZZVDUYOS-HRGUGZIWSA-N (1E,4E,8E)-alpha-humulene Chemical compound C\C1=C/CC(C)(C)\C=C\C\C(C)=C\CC1 FAMPSKZZVDUYOS-HRGUGZIWSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 206010051511 Viral diarrhoea Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 2
- 229930006722 beta-pinene Natural products 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- QAEBWUAXKZCQNZ-UHFFFAOYSA-N 1-(2-hydroxy-3-methyl-6-propan-2-ylphenyl)ethanone Chemical compound CC(C)C1=CC=C(C)C(O)=C1C(C)=O QAEBWUAXKZCQNZ-UHFFFAOYSA-N 0.000 description 1
- IOAISUCAQCEHTA-UHFFFAOYSA-N 5-methyl-2-propan-2-ylphenol Chemical group CC(C)C1=CC=C(C)C=C1O.CC(C)C1=CC=C(C)C=C1O IOAISUCAQCEHTA-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000009711 Huoxiang-zhengqi Substances 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000422846 Sequoiadendron giganteum Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical compound [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses one kind of elsholizia volatile oil granule preparation and its quality control method. The elsholizia volatile oil granule preparation of the present invention have the functions of resisting virus, resisting bacteria, resisting inflammation, stopping diarrhea, relieving pain and allaying fever, and can also suppress sthenic gastrointestinal function.
Description
Technical field
The present invention relates to a kind of Chinese medicine extract preparation and preparation method thereof, particularly relate to a kind of treatment diarrheal Herba Moslae extract granular preparation and preparation method thereof.
Background technology
Diarrhoea (infectious, non-infectious) sickness rate height, also higher in the certain areas case fatality rate, be transworld serious problems.The traditional Chinese medical science is to the then determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs of carrying out of diarrheal treatment more, cold-damp syndrome person huoxiang zhengqi powder master it, damp-heat syndrome person GEGEN QINLIAN TANG master it, dyspepsia card person lenitive pill master it, stagnation of liver-QI takes advantage of spleen person's tongxieyao formula master it, weakness of the spleen and stomach person SHENLING BAISHU SAN master it, kidney yang deficiency card person SISHEN WAN master it.So also there is the soil single-prescription of employing that gastroenteritis is carried out the treatment according to differentiation of diseases person.In the last few years, the report of Chinese traditional treatment viral diarrhea was many, but it is less to form the new drug person.The characteristics of Chinese medicine are to be good at recuperating gastrointestinal tract function, few side effects, but the action intensity of pathogen slightly is inferior to Western medicine.How modern medicine treats with the physical exercise therapy of antimicrobial drug fluid,matching infectious diarrhea, has obviously improved curative effect.The research of nearly microbial ecological agent has during the last ten years caused scholar's attention with application, has carried out vaccine research simultaneously, but owing to cause that the diarrheal pathogen is a lot, lacks cross immunity each other, so the development of vaccine is made slow progress always.Along with going deep into of research, also more and more clearer to the toxic and side effects of antimicrobial drug, as toxicity and gastrointestinal reaction, anaphylaxis and superinfection etc. to kidney, liver, neural spirit, blood.At present viral diarrhea is still lacked specific medicine, the report that external useful lactobacillus, interferon, virazole etc. are treated, domestic useful viral infection chicken, the preparation antibody preparation carries out therapist from ovum gallinaceum then, but still among research and development.In recent years developed the rotavirus live vaccine, among applying.According to the data of WHO, it is inferior that the whole world annual diarrhoea case can reach 30-50 hundred million examples, has 500-1000 ten thousand cases dead because of serious diarrhoea approximately.Inferior, non-, draw the area below 5 years old among the child, annual diarrhoea person is taken place more than 1,000,000,000 person-times, the dead about 5,000,000.According to reports, China suffers from diarrhoea for annual about 8.36 hundred million person-times, and wherein child below 5 years old accounts for 2.09 hundred million person-times, accounts for 1/4.According to Ministry of Public Health in 1993 report, China's acute gastroenteritis two all prevalences are that 11.74%, two all acute diseases constitute by the disease kind and account for 8.36%, come after acute nasopharyngitis and the influenza, occupy ill the 3rd of two weeks of the resident of urban and urual areas of whole country.Rotavirus is to be found by Bishop etc. in 1973.1.4 hundred million person-times of rotavirus diarrhea can take place every year in whole world child below 5 years old, and death can reach 1,000,000 people.Rotavirus is the important cause of disease of infantile diarrhea, has found to cause the one-tenth Human reoviruslike agent of adult diarrhea afterwards again.
Summary of the invention
The object of the invention is to provide a kind of treatment diarrheal Herba Moslae extract preparation.
The object of the invention also is to provide the method for quality control of Herba Moslae and extract thereof.
The present invention seeks to be achieved through the following technical solutions:
The preparation of Herba Moslae volatile oil: the Herba Moslae herb, cutting adds 6-10 times of water gaging, and vapor distillation extracted 4-8 hour, isolated the volatilization oil reservoir, promptly.
Volatile oil of the present invention (MOLA oil) is yellowish supernatant liquid, and relative density (20) is 0.9572g/ml, index of refraction 1.51.Must not be lower than 55% through gas chromatography mass spectrometry chromatography main component thymol and carvacrol content, meet the requirement of two kind new medicines.Qualitative and the relative quantification research of crude drug volatile oil component, known component is a thymol (Thymol) 58.131%, carvacrol (Cavacrol) 11.946%, cymol (P-Cymene) 10.274%, (γ-Terpinene) 5.733% for γ-Song Youxi, acetyl thymol (Thymol Acetate) 2.626%, (β-Myrcene) 1.832% for β-myrcene, a-humulene (a-Humulene) 1.638%, limonene (Limonene) 1.564%, trans-caryophyllene (trans-Caryophyllene) 0.970%, a-terpineol (a-Terpinene) 0.718%, Borneolum Syntheticum (Borneol) 0.514%, acetyl carvacrol (CavacrolAcetate) 0.384%, (β-Pinene) 0.317% for nopinene, a-pinene (a-Pinene) 0.256%, known component adds up to 96.5%, and volatile oil component is stable, place one-year age, each main component and relative scale thereof do not have significant change.
The preparation method of granular preparation of the present invention (not drawing granule): get Herba Moslae volatile oil 20-40 weight portion, add equivalent 85-95% ethanol dilution; Beta-schardinger dextrin-13-15 doubly measures, and it is miscible to add 1500ml hot water, and 30-45 ℃ of insulation mixes stirs 3-8min, by colloid mill enclose 2-4 time, refrigerator was placed more than 8-14 hour, sucking filtration, clathrate 30-45 ℃ forced air drying 4-8 hour, sieve, add dextrin to the 800-1000 weight portion, add magnesium stearate 1-3 weight portion, aspartame 1-3 weight portion, mixing, dry-pressing is granulated, granulate is made granule, and packing promptly.
The method of quality control of granular preparation of the present invention comprises following discriminating and/or assay:
Assay: the preparation of reference substance solution, precision takes by weighing thymol reference substance 8mg and thymol reference substance 4mg, puts in the 100ml measuring bottle, adds methanol to scale, shake up, precision is measured above-mentioned solution 2.5ml, puts in the 10ml measuring bottle, adds methanol to scale, shake up, that is, contain thymol 20 μ g among every ml, contain carvacrol 10 μ g.The content under the content uniformity item is got in the preparation of need testing solution, and porphyrize is got 0.12g, the accurate title, decide, and puts in the tool plug conical flask, and precision adds methanol 20ml, close plug, claim to decide weight, supersound process 30 minutes is put cold, claim to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, precision is measured subsequent filtrate 2ml, puts in the 10ml measuring bottle, add methanol and be diluted to scale, shake up, promptly.Assay method is measured according to high performance liquid chromatography (2000 editions one appendix VI D of Chinese Pharmacopoeia).Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; 50-70: 50-30: 1-3 methanol-water-glacial acetic acid is a mobile phase; The detection wavelength is 276nm.Number of theoretical plate calculates by the thymol peak should be not less than 10000, calculates by the carvacrol peak and should be not less than 15000.Algoscopy, accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing inject chromatograph of liquid, measure, promptly.Every g granule contains thymol (C
10H
14O) and carvacrol (C
10H
14O) total amount must not be less than 15mg.
Differentiate: by not drawing particle content measuring method, high-efficient liquid phase chromatogram has corresponding absworption peak in the retention time identical with the carvacrol reference substance with thymol.
Pharmaceutical preparation of the present invention and middle removing dampness, induce sweat and bring down a fever.Cure mainly the diarrhoea that diarrhoea, stomachache, fever with aversion to cold, head-body-pain and rotavirus or some bacterial infection cause.
Of the present inventionly do not draw particulate pharmacodynamic study result to show, do not draw granule to have following function:
1. do not draw particulate antivirus action: 12.5～25nl/ml not draw granule can suppress children's's rotavirus RDTA-I type (Wa strain) growth and breeding on African green monkey kidney cell.
2. do not draw particulate antibacterium effect: do not draw granule can reduce Salmonella enteritidis abdominal cavity infection mortality of mice (P＜0.05); Can reduce the content (P＜0.05～0.01) of pathogenic bacterium in the mice stool of Salmonella enteritidis peroral infection; External, to common pathogens such as Escherichia coli, Shiga bacillus, proteus vulgaris, staphylococcus aureus, staphylococcus epidermidiss, stronger inhibition growth effect is arranged, and test is with in the 44 strain bacterial strains, and minimum inhibitory concentration≤1ul oil/ml accounts for 79.5%.
3. do not draw particulate anti-diarrhea effect: loose stool rate, diarrhea rate, diarrhoea index and the diarrhoea degree (P＜0.05～0.001) that reduce the diarrhoea model mice due to the 100% Folium Sennae decoct significantly.
4. do not draw the influence of granule to gastrointestinal function: this medicine can reduce normally and hyperfunction mouse small intestine propulsion functions (P＜0.05～0.001) due to the neostigmine, prolong defecation time, reduce defecation quantity (P＜0.05～0.001), slow down gastric emptying motion (P＜0.01～0.001), intestinal smooth muscle excitement due to the reduction stomachial secretion function (P＜0.001), stripped intestinal smooth muscle spontaneous vasomotion of inhibition normal guinea pig and acetylcholine.
5. do not draw particulate analgesic effect: do not draw granule to reduce very significantly by the mouse writhing number due to 0.7% acetic acid (all P＜0.001), suppression ratio reaches 51.3～55.7%.
6. do not draw particulate antiinflammatory action: do not draw granule to suppress significantly by dimethylbenzene induced mice ear swelling (P＜0.01～0.001), suppress the vascular permeability (P＜0.05～0.001) that histamine causes significantly, suppress abdominal cavity leukoplania (P＜0.05～0.001) due to the sodium carboxymethyl cellulose.
7. do not draw particulate antipyretic effect: do not draw granule that saccharomycetic rat temperature is raise and endotoxin due to the rabbit body temperature rising inhibitory action (P＜0.05～0.001) is significantly all arranged.
Following experimental example is used to further specify the present invention.
Experimental example:Do not draw granule to suppress the effect of children's's rotavirus ROTA-I type (Wa strain)
Materials and methods:
1. medicine: be subjected to reagent not draw granule, MOLA oil is directly used in test, and is faint yellow, proportion 0.95726g/ml, and 16mg oil/g crude drug, lot number: 20000601, Beijing big tree institute of Pharmaceutical Research provides.Getting the 0.5ml MOLA oil adds the 0.5ml tween 80 (Shanghai the 18 pharmaceutical factory produces, lot number: add the dilution of 4ml growth-promoting media after 960520) being mixed.It is standby to put 4 ℃ of refrigerators.
Contrast medicine GEGEN QINLIAN DIWAN, the Liuzhou city pharmaceutical factory of traditional Chinese medicine produces, and accurate word (1991) is defended No. 017004 in osmanthus, lot number: 990721.Get 10 milliliters of dissolvings of 1g medicine adding distil water, 2000 rev/mins, centrifugal 10 minutes, get the supernatant water-bath and boil sterilization in 10 minutes, put 4 ℃ of refrigerators and preserve.
The above-mentioned medicinal preceding pH=7.2 that transfers
2. cell: African green monkey kidney (Vero) passage cell, the cell that grows up to monolayer is individual cells through the digestion of trypsinization liquid, is made into 60,000 cell/ml with growth-promoting media, inserts the cell pipe, the 1ml/ pipe.
3. viral: children's's rotavirus ROTA-1 type (Wa strain), TCID
50Be 10
-7, provide by Virology Inst., China Academy of Preventive Medicine Sciences, during test with 100 TCID
500.1ml.Before the Wa strain is used, add 37 ℃ of water-baths of 0.05ml pancreatin (200ug/ml) 30 minutes with 1ml virus liquid.
4. reagent: Eagles MEM dry powder, U.S. GIBCO product.Hyclone, the Tianjin Blood Research Institute is produced; Lot number: 9925.L-glutaminate, Sigma import packing, lot number: 911015.Penicillin, streptomycin.
The reagent preparation:
Growth-promoting media: Eagles adds 1% mycillin, 1% glutamine, 10% calf serum, with preceding accent PH=7.4.
Keep liquid: Eagles adds 1% mycillin, 1% glutamine, and 200ug/ml pancreatin (final concentration is 2ug/ml) is with preceding accent PH=7.4.
Cell dissociation buffer: 0.25% pancreatin, with no calcium magnesium phosphate buffer preparation.
5. test articles for use and instrument:
Culture bottle, test tube, measuring pipette, incubator, refrigerator, baking box, water bath, low temperature refrigerator, liquid nitrogen container etc. are homemade.
6. test method:
(1) MOLA oil, GEGEN QINLIAN DIWAN and tween 80 are to the toxic action of Vero cell: will dilute good medicine, tween 80 inserts and grows up in the test tube of cell monolayer, puts 37 ℃ of incubators and cultivates, every day, observation of cell changed.
(2) medicine is to the direct killing effect of virus: put 37 ℃ of incubators 1 hour after will diluting good medicine and viral mixed in equal amounts.Access grows up in the test tube of cell monolayer then, and every pipe 0.2ml is put 37 ℃ of absorption 1 hour.Keep liquid 1ml with keeping to add after liquid is washed twice.Put 37 ℃ of incubators and cultivate, observation of cell pathological changes every day (CPE), when virus control occurs ++ ++ the time, termination test.
(3) medicine inhibitory action that virus is bred in cell: the virus that will handle inserts in the cell pipe, every pipe 0.1ml is put 37 ℃ of absorption 1 hour, with keep liquid wash after twice add respectively contain different pharmaceutical concentration keep liquid 1ml, put 37 ℃ of cultivations, every day the observation of cell pathological changes, when the virus control pipe occurs ++ ++ the time, termination test.
Annotate: cytopathy :+25%, ++ 50%, +++75%, ++ ++ 100%.
More than medicine contrast, virus control, cell contrast are established in test simultaneously, and every test group 4 solencytes repeat to do experiment 2 times.
The result:
1. MOLA oil the results are shown in Table 1 to the toxicity test of Vero cell.
Table 1 MOLA oil is to the toxicity test result of Vero cell
Group drug level/ml cell pipe is counted cytotoxicity pipe number
100nl 4 4
50nl 4 0
MOLA oil
25nl 4 0
12.5nl 4 0
5mg 4 4
GEGEN QINLIAN DIWAN 2.5mg 40
1.25mg 4 0
200nl 4 2
Tween 80
100nl 4 0
Vero contrasts 40
4 concentration MOLA oil are inserted the cell pipe respectively, and final concentration is 100,50,25,12.5nl/ml.Each concentration 4 pipe was observed 7 days.Pair cell was toxic when MOLA oil concentration was 100nl/ml as a result, and concentration is 50,25, and pair cell does not have toxicity during 12.5nl/ml; Pair cell is toxic during GEGEN QINLIAN DIWAN 5mg/ml, and pair cell does not have toxicity when 2.5mg/ml and 1.25mg/ml; Pair cell does not have toxicity during tween 80 100nl/ml.
2. MOLA oil is to the direct killing effect result of the test of virus: the results are shown in Table 2.
Table 2 MOLA oil is to the direct killing effect result of the test of virus
The positive pipe of group drug level/ml inoculated tube number number negative tube number
50nl 8 8 0
The MOLA oil group
25nl 8 8 0
10mg 8 8 0
The GEGEN QINLIAN DIWAN group
5mg 8 8 0
100nl 8 8 0
The tween 80 group
50nl 8 8 0
Wa strain matched group 880
Cell matched group 808
It is as shown in the table: each administration group of MOLA oil does not have direct deactivation to children's's rotavirus ROTA-1 type.
MOLA oil to virus in intracellular breeding inhibitory action result of the test: the results are shown in Table 3.
Table 3: MOLA oil to virus in intracellular breeding inhibitory action result of the test:
Group drug level/positive the pipe of ml pipe number negative tube
25nl 8 0 8
12.5nl 8 0 8
The MOLA oil group
6.25nl 8 2 6
3.12nl 8 8 0
2.5mg 8 8 0
The GEGEN QINLIAN DIWAN group
1.25mg 8 8 0
100nl 8 8 0
The tween 80 group
50nl 8 8 0
The Wa strain contrasts 880
Cell contrasts 808
It is as shown in the table, when MOLA oil concentration is 25nl/ml, 12.5nl/ml, can suppress virus fully in intracellular breeding, when concentration is 6.25nl/ml, virus is bred certain inhibitory action in cell, when concentration is 3.1nl/ml virus being bred in cell does not have inhibitory action.GEGEN QINLIAN DIWAN, each concentration group of tween 80 is bred in cell virus does not have inhibitory action.
Embodiment 1:Get Herba Moslae volatile oil 33.3g, add equivalent 95% ethanol dilution; Beta-schardinger dextrin-500g, it is miscible to add 1500ml hot water, and 40 ℃ of insulations mix stirs 5min, by colloid mill enclose 3 times, refrigerator was placed more than 12 hours, sucking filtration, 80 mesh sieves are crossed in 40 ℃ of forced air dryings of clathrate 6 hours, add dextrin to 996g, add magnesium stearate 2g, aspartame 2g, mixing, dry-pressing is granulated, 20-80 order granulate is made the 1000g granule, and packing promptly.Every packing 1g.3 times on the one, one time 1 bag.
Embodiment 2:The method of quality control of granular preparation of the present invention
Assay: the preparation of reference substance solution, precision takes by weighing thymol reference substance 8mg and thymol reference substance 4mg, puts in the 100ml measuring bottle, adds methanol to scale, shake up, precision is measured above-mentioned solution 2.5ml, puts in the 10ml measuring bottle, adds methanol to scale, shake up, that is, contain thymol 20 μ g among every ml, contain carvacrol 10 μ g.The content under the content uniformity item is got in the preparation of need testing solution, and porphyrize is got 0.12g, the accurate title, decide, and puts in the tool plug conical flask, and precision adds methanol 20ml, close plug, claim to decide weight, supersound process 30 minutes is put cold, claim to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, precision is measured subsequent filtrate 2ml, puts in the 10ml measuring bottle, add methanol and be diluted to scale, shake up, promptly.Assay method is measured according to high performance liquid chromatography (2000 editions one appendix VI D of Chinese Pharmacopoeia).Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; 60: 40: 2 methanol-water-glacial acetic acid are mobile phase; The detection wavelength is 276nm.Number of theoretical plate calculates by the thymol peak should be not less than 10000, calculates by the carvacrol peak and should be not less than 15000.Algoscopy, accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing inject chromatograph of liquid, measure, promptly.Every g granule contains thymol (C
10H
14O) and carvacrol (C
10H
14O) total amount must not be less than 15mg.
Differentiate: by not drawing particle content measuring method, high-efficient liquid phase chromatogram has corresponding absworption peak in the retention time identical with the carvacrol reference substance with thymol.
Claims (4)
1, a kind of Herba Moslae volatile oil granular preparation is characterized in that said preparation made by following method:
Get Herba Moslae volatile oil 20-40 weight portion, add equivalent 85-95% ethanol dilution; Beta-schardinger dextrin-13-15 doubly measures, and it is miscible to add 1500ml hot water, and 30-45 ℃ of insulation mixes stirs 3-8min, by colloid mill enclose 2-4 time, refrigerator was placed more than 8-14 hour, sucking filtration, clathrate 30-45 ℃ forced air drying 4-8 hour, sieve, add dextrin to the 800-1000 weight portion, add magnesium stearate 1-3 weight portion, aspartame 1-3 weight portion, mixing, dry-pressing is granulated, granulate is made granule, and packing promptly.
2, a kind of Herba Moslae volatile oil granular preparation as claimed in claim 1 is characterized in that said preparation made by following method:
Get Herba Moslae volatile oil 33.3g, add equivalent 95% ethanol dilution; Beta-schardinger dextrin-500g, it is miscible to add 1500ml hot water, and 40 ℃ of insulations mix stirs 5min, by colloid mill enclose 3 times, refrigerator was placed more than 12 hours, sucking filtration, 80 mesh sieves are crossed in 40 ℃ of forced air dryings of clathrate 6 hours, add dextrin to 996g, add magnesium stearate 2g, aspartame 2g, mixing, dry-pressing is granulated, 20-80 order granulate is made the 1000g granule, and packing promptly.
3, the method for quality control of preparation as claimed in claim 1 or 2 is characterized in that this method of quality control contains following discriminating and/or assay:
Assay: the preparation of reference substance solution, precision takes by weighing thymol reference substance 8mg and thymol reference substance 4mg, puts in the 100ml measuring bottle, adds methanol to scale, shake up, precision is measured above-mentioned solution 2.5ml, puts in the 10ml measuring bottle, adds methanol to scale, shake up, that is, contain thymol 20 μ g among every ml, contain carvacrol 10 μ g; The content under the content uniformity item is got in the preparation of need testing solution, and porphyrize is got 0.12g, the accurate title, decide, and puts in the tool plug conical flask, and precision adds methanol 20ml, close plug, claim to decide weight, supersound process 30 minutes is put cold, claim to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, precision is measured subsequent filtrate 2ml, puts in the 10ml measuring bottle, add methanol and be diluted to scale, shake up, promptly; Assay method is according to high effective liquid chromatography for measuring; Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; 50-70: 50-30: 1-3 methanol-water-glacial acetic acid is a mobile phase; The detection wavelength is 276nm; Number of theoretical plate calculates by the thymol peak should be not less than 10000, calculates by the carvacrol peak and should be not less than 15000; Algoscopy, accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing inject chromatograph of liquid, measure, promptly; The total amount that every g granule contains thymol and carvacrol must not be less than 15mg;
Differentiate: by not drawing particle content measuring method, high-efficient liquid phase chromatogram has corresponding absworption peak in the retention time identical with the carvacrol reference substance with thymol.
4, method of quality control as claimed in claim 3 is characterized in that in this method with 60: 40: 2 methanol-water-glacial acetic acid being mobile phase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153996 CN1248701C (en) | 2002-12-09 | 2002-12-09 | Elsholizia extract granule for treating diarrhea and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153996 CN1248701C (en) | 2002-12-09 | 2002-12-09 | Elsholizia extract granule for treating diarrhea and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1506094A true CN1506094A (en) | 2004-06-23 |
| CN1248701C CN1248701C (en) | 2006-04-05 |
Family
ID=34235400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02153996 Expired - Fee Related CN1248701C (en) | 2002-12-09 | 2002-12-09 | Elsholizia extract granule for treating diarrhea and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1248701C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451228A (en) * | 2010-10-26 | 2012-05-16 | 中国医学科学院药用植物研究所 | Preparation method and application of elsholtzia densa volatile oil with antibacterial and antiviral effects |
| CN103146484A (en) * | 2013-02-28 | 2013-06-12 | 青海红璟天生物科技有限公司 | Method for fast preparing betadex embedded object of rhododendron anthopogonoide volatile oil |
| CN105960167A (en) * | 2014-01-14 | 2016-09-21 | 包装,运输及物流技术研究所(Itene) | Antimicrobial compositions for food packaging consisting of salicylaldehyde and carvacrol, thymol or their mixture |
| CN109419846A (en) * | 2017-08-31 | 2019-03-05 | 安徽天康(集团)股份有限公司 | A kind of application of Herba Moslae volatile oil in treatment norovirus infectious diarrhea |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610853B (en) * | 2013-12-13 | 2015-03-04 | 华润三九（郴州）制药有限公司 | Angelica sinensis and ligusticum wallichii tablet for regulating menstruation and preparation method of angelica sinensis and ligusticum wallichii tablet |
-
2002
- 2002-12-09 CN CN 02153996 patent/CN1248701C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451228A (en) * | 2010-10-26 | 2012-05-16 | 中国医学科学院药用植物研究所 | Preparation method and application of elsholtzia densa volatile oil with antibacterial and antiviral effects |
| CN103146484A (en) * | 2013-02-28 | 2013-06-12 | 青海红璟天生物科技有限公司 | Method for fast preparing betadex embedded object of rhododendron anthopogonoide volatile oil |
| CN105960167A (en) * | 2014-01-14 | 2016-09-21 | 包装,运输及物流技术研究所(Itene) | Antimicrobial compositions for food packaging consisting of salicylaldehyde and carvacrol, thymol or their mixture |
| CN109419846A (en) * | 2017-08-31 | 2019-03-05 | 安徽天康(集团)股份有限公司 | A kind of application of Herba Moslae volatile oil in treatment norovirus infectious diarrhea |
| CN109419846B (en) * | 2017-08-31 | 2021-07-16 | 安徽天康(集团)股份有限公司 | Application of herba Moslae volatile oil in treating norovirus infectious diarrhea |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1248701C (en) | 2006-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1839988A (en) | Traditional Chinese medicine composition for treating fowl influenza, its preparation method and uses | |
| CN112472698B (en) | Application of bromophenol-pyrazoline compounds in treatment of porcine coronavirus diseases | |
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN101850008A (en) | Bacillus Ling oral liquid and preparation method thereof | |
| KR20110132407A (en) | Plant extract compositions for prevention and treatment of influenza | |
| CN101596246B (en) | Smoked plum extractive and wild jujube seed extractive compound preparation as well as preparation method and application thereof | |
| CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
| CN101869611A (en) | Admixture capable of repelling chicken coccidiosis and stopping dysentery and preparation method thereof | |
| CN105641031A (en) | Compound pharmaceutical composition for strengthening body resistance and removing toxin, use and feed thereof | |
| CN1283274C (en) | Elsholizia extract capsule for treating diarrhea and its prepn | |
| CN1248701C (en) | Elsholizia extract granule for treating diarrhea and its prepn | |
| CN103142683B (en) | Be used for the treatment of Chinese medicinal perfusion liquid containing Herba Sophorae alopecuroidis total alkali of bovine mastitis and endometritis and preparation method thereof | |
| CN1267110C (en) | Elsholizia extract prepn and its quality control method and new use | |
| CN1269498C (en) | Chinese medicinal composition possessing antipyretic and its preparation method and quality control method | |
| CN104274511A (en) | Traditional Chinese medicinal composition for veterinary use and application thereof | |
| CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN1876045A (en) | A Chinese medicinal composition, its preparation process and quality control method | |
| CN100347539C (en) | Herba Moslae quality control | |
| CN106389717A (en) | Piglet drug-resistant colibacillosis treating traditional Chinese medicine composition | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
| CN104784327A (en) | Traditional Chinese veterinary medicine composition for treating respiratory diseases of chicken and preparation method thereof | |
| CN101045103A (en) | Traditional Chinese medicine for treating arthrolithiasis of fowl, its preparating method and use | |
| CN104491011B (en) | A kind of rotavirus for the treatment of causes Chinese medicine composition of baby diarrhea and preparation method thereof | |
| CN1879736A (en) | Antibacterial Chinese medicinal composition for birds and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG NEW AGE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHANG RUIXIANG Effective date: 20100426 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100028 NO.7, 2/F, BUILDING 57, XIBAHE DONGLI, CHAOYANG DISTRICT, BEIJING CITY TO: 273400 NO.1, NORTH OUTER RING ROAD, FEI COUNTY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100426 Address after: 273400 Shandong province Feixian County North Ring Road No. 1 Patentee after: Shandong Xinshidai Pharmaceutical Industry Co., Ltd. Address before: 100028 Beijing Chaoyang District City 57 east 2 floor No. 7 Patentee before: Zhang Ruixiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060405 Termination date: 20191209 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |